Charles Cohen Biography and Net Worth

Director of Exelixis

Charles Cohen, Ph.D., has been a director since November 1995. Dr. Cohen is an independent investor and from March 2015 to May 2019, he served as Chief Executive Officer and as a member of the board of directors of Perform Biologics, Inc., a privately held biotechnology start-up company. Previously, Dr. Cohen served as Chief Executive Officer and as a member of the board of directors of On Target Therapeutics, LLC, a privately held biotechnology start-up company, from June 2015 to June 2017. From May 2007 to December 2015, Dr. Cohen was a managing director of Synthesis Capital (formerly Advent Healthcare Ventures), a venture capital firm. From 2003 to 2007, Dr. Cohen was Vice President of Advent International, a global private equity firm.

From 2000 to 2002, Dr. Cohen was the Chief Executive Officer of Cellzome AG, a post-genomics biotechnology company. Prior to that time, Dr. Cohen co-founded Creative BioMolecules, Inc., a biotechnology company, in 1982 and was one of its directors and its Chief Executive Officer from 1985 to 1995. Dr. Cohen served as a member of the board of directors of the following publicly held companies: Anadys Pharmaceuticals, Inc., a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C, from 2000 to 2005; and Anesiva, Inc., a biopharmaceutical company focused on the development and commercialization of novel pharmaceutical products for pain management from 2005 to 2007. Dr. Cohen also served as the Chairman of the Supervisory Board of Cellzome AG, prior to its acquisition by GlaxoSmithKline in May 2012, and as the Chief Executive Officer of several other companies. Dr. Cohen received his B.A. from the State University of New York at Buffalo and his Ph.D. from New York University School of Medicine.

What is Charles Cohen's net worth?: The estimated net worth of Charles Cohen is at least $7.37 million as of February 24th, 2021. Dr. Cohen owns 221,375 shares of Exelixis stock worth more than $7,369,574 as of December 22nd. This net worth evaluation does not reflect any other investments that Dr. Cohen may own. Learn More about Charles Cohen's net worth.
How do I contact Charles Cohen?: The corporate mailing address for Dr. Cohen and other Exelixis executives is 1851 Harbor Bay Parkway, Alameda CA, 94502. Exelixis can also be reached via phone at (650) 837-7000 and via email at [email protected]. Learn More on Charles Cohen's contact information.
Has Charles Cohen been buying or selling shares of Exelixis?: Charles Cohen has not been actively trading shares of Exelixis in the last ninety days. Most recently, Charles Cohen sold 40,000 shares of the business's stock in a transaction on Wednesday, February 24th. The shares were sold at an average price of $22.69, for a transaction totalling $907,600.00. Following the completion of the sale, the director now directly owns 221,375 shares of the company's stock, valued at $5,022,998.75. Learn More on Charles Cohen's trading history.
Who are Exelixis' active insiders?: Exelixis' insider roster includes Dana Aftab (EVP), Charles Cohen (Director), Carl Feldbaum (Director), Maria Freire (Director), Maria Freire (Director), Alan Garber (Director), Patrick Haley (EVP), Jeffrey Hessekiel (EVP), David Johnson (Director), Peter Lamb (EVP), Vincent Marchesi (Director), Michael Morrissey (CEO), Stelios Papadopoulos (Director), George Poste (Director), Gisela Schwab (CMO), Christopher Senner (CFO), Lance Willsey (Director), and Jack Wyszomierski (Director). Learn More on Exelixis' active insiders.
Are insiders buying or selling shares of Exelixis?: In the last year, Exelixis insiders bought shares 3 times. They purchased a total of 615,000 shares worth more than $12,668,000.00. In the last year, insiders at the biotechnology company sold shares 20 times. They sold a total of 739,715 shares worth more than $21,619,607.83. The most recent insider tranaction occured on November, 29th when EVP Jeffrey Hessekiel sold 60,000 shares worth more than $2,200,200.00. Insiders at Exelixis own 2.9% of the company. Learn More about insider trades at Exelixis.
Information on this page was last updated on 11/29/2024.

Charles Cohen Insider Trading History at Exelixis

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/24/2021	Sell	40,000	$22.69	$907,600.00	221,375
2/25/2019	Sell	5,271	$22.18	$116,910.78	11,250
2/19/2019	Sell	248,180	$22.14	$5,494,705.20	148,180
5/9/2018	Sell	15,000	$21.42	$321,300.00	263,180
3/13/2017	Sell	10,000	$21.82	$218,200.00	238,180

Charles Cohen Buying and Selling Activity at Exelixis

Exelixis Company Overview

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Today's Range

Now: $33.29

$33.11

$33.68

50 Day Range

MA: $33.51

$26.24

$36.46

2 Week Range

Now: $33.29

$19.20

$36.97

Volume

7,648,822 shs

Average Volume

2,082,318 shs

Market Capitalization

$9.51 billion

P/E Ratio

21.34

Dividend Yield

N/A

Beta

0.52

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong

From Brownstone Research | Ad

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.